Molecular Mechanisms of Drug-Target Interactions in Neurodegenerative Disorders

Neurodegenerative disorders are illnesses that slowly damage the brain and nervous system over time. This happens because certain brain cells (called neurons) stop working properly and eventually die. Diseases like Alzheimer’s, Parkinson’s, Huntington’s, and ALS (also known as Lou Gehrig’s disease) fall into this category. Neurodegenerative disorders, such as Alzheimer's disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), are marked by progressive neuronal dysfunction and irreversible loss of brain function. Central to their pathology are molecular disturbances, including protein misfolding, oxidative stress, mitochondrial impairment, and disrupted cellular signaling pathways. Therapeutic development increasingly hinges on understanding drug-target interactions at the molecular level to effectively counteract these disease mechanisms. Key pharmacological strategies involve inhibition of pathogenic enzymes (e.g., β-secretase in Alzheimer’s disease), stabilization of misfolded proteins (e.g., alpha-synuclein in Parkinson’s disease), and modulation of neurotransmitter pathways, such as dopaminergic and cholinergic systems. Advances in structural biology and computational methods—such as molecular docking and high-throughput screening—have improved the identification of druggable targets, including orthosteric and allosteric binding sites, enhancing drug selectivity and efficacy. Crucially, central nervous system (CNS)-oriented drug design must overcome pharmacokinetic challenges, such as blood-brain barrier penetration and metabolic stability. Emerging modalities, including proteolysis-targeting chimeras (PROTACs), gene-silencing technologies, and AI-augmented compound screening platforms, offer promising avenues for the discovery of disease-modifying therapies. Collectively, these approaches represent a critical step toward addressing the longstanding therapeutic gaps in neurodegenerative disease management.